CorMedix

What CorMedix does

CorMedix Inc. is a publicly traded (NASDAQ: CRMD) specialty pharmaceutical company founded in 2006 and headquartered in Berkeley Heights, New Jersey, that develops and commercializes therapeutic products for life-threatening conditions in institutional care settings, with a portfolio centered on anti-infectives for cardiac, renal, and infectious disease indications. Its core asset, DefenCath (taurolidine and heparin), is the only FDA-approved antimicrobial catheter lock solution indicated to reduce catheter-related bloodstream infections (CRBSIs) in adult hemodialysis patients with central venous catheters; the product is built on a proprietary taurolidine platform whose mechanism disrupts bacterial cell walls, prevents biofilm formation by destroying fimbriae, and neutralizes bacterial exotoxins and endotoxins, and is not susceptible to known resistance mechanisms. Following the August 2025 acquisition of Melinta Therapeutics for $300 million, CorMedix operates a diversified specialty anti-infective portfolio that also includes REZZAYO (rezafungin, an echinocandin approved for candidemia/invasive candidiasis with a Phase III prophylaxis indication pending), MINOCIN, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL, all commercialized through a direct field-based sales organization targeting hospitals, outpatient dialysis providers, infusion clinics, and hematology/oncology centers in the United States. CorMedix generated $311.7M in reported FY2025 revenue and $127.4M in Q1 2026 revenue, with FY2026 guidance of $325-345M; revenue is generated through institutional pharmaceutical product sales subject to CMS reimbursement dynamics including a TDAPA-to-post-TDAPA add-on adjustment transition for DefenCath effective July 1, 2026.

Name

CorMedix

Legal name

CorMedix Inc.

Website

https://cormedix.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

CorMedix is a specialty pharmaceutical company that commercializes DefenCath, the only FDA-approved antimicrobial catheter lock solution for hemodialysis patients, and a portfolio of acquired hospital anti-infective products targeting US hospitals, dialysis providers, and hematology/oncology centers.

Ownership category

akta.pro rank

Product category

Specialty Pharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Infusion Sets, Catheters & Pump Consumables (HLAHAIAH)

akta.pro secondary industry

Vascular Access Devices (AV Grafts, Catheters, Fistula Accessories) (HLAHAKAE)

Keywords

• Antimicrobial catheter lock
• Specialty pharmaceuticals
• Anti-infective therapies
• Hospital pharmaceuticals
• Hemodialysis infection prevention

Headquarters

HQ city

Bridgewater

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. DefenCath product sales: Revenue generated from sales of DefenCath (taurolidine and heparin) for prevention of catheter-related bloodstream infections in adult hemodialysis patients. DefenCath contributed $97.5 million in Q1 2026 and $91.2 million in Q4 2025. Full-year 2025 DefenCath net sales were $258.8 million.
2. Melinta anti-infective portfolio: Revenue from the acquired Melinta Therapeutics portfolio including REZZAYO, MINOCIN, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. The Melinta portfolio contributed $29.9 million in Q1 2026 and $37.4 million in Q4 2025, with pro forma full-year 2025 contribution of approximately $140 million.
3. REZZAYO future revenue (pending FDA approval for prophylaxis): Revenue anticipated from expanded REZZAYO indication for prophylaxis of invasive fungal diseases, pending FDA sNDA submission in 2H26 following positive Phase III ReSPECT topline results. CorMedix estimates potential US market opportunity exceeding $2 billion for REZZAYO in prophylaxis.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels4 records

Core offering

CorMedix develops and commercializes specialty pharmaceutical products for life-threatening cardiac, renal, and infectious diseases. The company's leading product, DefenCath, is an FDA-approved antimicrobial catheter lock solution (taurolidine and heparin) used to reduce catheter-related bloodstream infections in patients with central venous catheters for hemodialysis. Its broader commercial portfolio includes anti-infective and cardiovascular products such as REZZAYO, MINOCIN for Injection, VABOMERE, ORBACTIV/KIMYRSA, BAXDELA, and TOPROL-XL.

Product overview

CorMedix is a diversified specialty biopharmaceutical company commercializing therapeutic products for life-threatening conditions in institutional care settings. The portfolio centers on DefenCath (taurolidine and heparin), an FDA-approved catheter lock solution for preventing bloodstream infections in hemodialysis patients, supplemented by an acquired portfolio of anti-infective products from Melinta Therapeutics including REZZAYO (rezafungin), MINOCIN, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and TOPROL-XL. The company is also advancing pipeline programs including REZZAYO for fungal prophylaxis indication and DefenCath for total parenteral nutrition applications.

Differentiator

Problem solved

Functional benefit

Brands

• DefenCath: FDA-approved antimicrobial catheter lock solution (taurolidine and heparin) for preventing catheter-related bloodstream infections in hemodialysis patients
• REZZAYO
• MINOCIN
• VABOMERE
• ORBACTIV
• BAXDELA
• KIMYRSA
• TOPROL-XL

Products and services

• DefenCath DefenCath is an FDA-approved antimicrobial catheter lock solution combining taurolidine and heparin, indicated to reduce the incidence of catheter-related bloodstream infections (CRBSIs) in adult patients with central venous catheters for hemodialysis. It is sold to hospitals, dialysis centers, and specialty distributors and used by nephrologists, infectious disease specialists, and vascular access teams.
• REZZAYO (rezafungin) REZZAYO is an antifungal (rezafungin) product in CorMedix's anti-infective portfolio for the treatment of serious fungal infections, sold through hospital and specialty channels.
• MINOCIN (minocycline) for Injection MINOCIN for Injection is a tetracycline-class antibiotic indicated for the treatment of infections caused by susceptible strains of designated microorganisms, distributed to hospitals and specialty care settings.
• VABOMERE (meropenem and vaborbactam) VABOMERE is a combination antibacterial (meropenem and vaborbactam) indicated for the treatment of complicated urinary tract infections and other serious bacterial infections, sold to hospitals and infectious disease specialists.
• ORBACTIV (oritavancin) ORBACTIV is an antibacterial (oritavancin) used for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive organisms, distributed through hospital and specialty pharmacy channels.
• KIMYRSA (oritavancin) KIMYRSA is an oritavancin-based antibacterial offering a shorter infusion option for acute bacterial skin and skin structure infections, sold via hospital outpatient and specialty channels.
• BAXDELA (delafloxacin) BAXDELA is a fluoroquinolone antibacterial (delafloxacin) indicated for the treatment of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, sold to hospitals and specialty providers.
• TOPROL-XL (metoprolol succinate) TOPROL-XL is a cardiovascular product (metoprolol succinate extended-release) indicated for the treatment of angina, heart failure, and hypertension, part of CorMedix's broader commercial portfolio serving cardiac patients.

Quantifiable outcome

• 71% reduction in catheter-related bloodstream infection risk (CRBSI) in hemodialysis patients (LOCK-IT-100 Phase III, p=0.0006)
• +6 more outcomes

Named customers2 records

Segments4 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Four partnerships are on record, tiered minor and core.

• TalpheraminorStrategic or Co-development Partner · 12 November 2025CorMedix made a strategic investment in Talphera and has the right to negotiate an acquisition of Talphera. Talphera's Niyad drug is expected to receive potential PMA approval in late 2026, with the NEPHRO study expected to complete in H1 2026.
• Melinta TherapeuticscoreStrategic or Co-development Partner · 7 August 2025CorMedix acquired Melinta Therapeutics in a deal valued at approximately $300 million in cash and stock in August 2025, transforming CorMedix into a diversified specialty pharmaceutical company with six approved anti-infective products. Melinta is now a wholly owned subsidiary of CorMedix and adds approximately $140 million in pro forma revenue to the combined entity.
• POETIC (Pediatric Oncology Therapeutic Investigators Consortium)minorStrategic or Co-development Partner · 1 January 2016Collaboration with POETIC to evaluate a novel formulation of taurolidine (CMDX-001) as investigational therapy for rare pediatric cancers including neuroblastoma and osteosarcoma. The collaboration advances preclinical studies and will determine clinical strategy once in vivo proof-of-concept is achieved.
• MundipharmacoreStrategic or Co-development PartnerMundipharma is the global sponsor of the Phase III ReSPECT clinical trial evaluating REZZAYO for prophylaxis of invasive fungal diseases. Mundipharma has commercial rights to rezafungin outside the United States and partnered with Melinta Therapeutics (a CorMedix subsidiary) for US distribution. The companies jointly announced positive topline results in April 2026 and plan to submit an sNDA to the FDA in 2H26.

Scale indicators14 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Citius Pharmaceuticals: Late-stage specialty biopharma focused on anti-infective and oncology assets, including an investigational catheter lock solution (Mino-Lok) directly competing with DefenCath in the catheter-related bloodstream infection space.
• ANI Pharmaceuticals: Specialty pharmaceutical company that develops, manufactures, and markets branded and generic prescription pharmaceuticals, including injectable anti-infectives — closely comparable to CorMedix's Melinta portfolio in hospital and acute care channels.
• Eagle Pharmaceuticals: Specialty pharma focused on injectable and hospital-based products, including anti-infectives and oncology supportive care, with a similar hospital sales force model and focus on differentiated reformulations — a direct analog to CorMedix's commercial approach.
• Melinta Therapeutics (subsidiary): Now a wholly-owned CorMedix subsidiary post the August 2025 acquisition; historically a direct peer as a hospital-focused anti-infective company commercializing MINOCIN, VABOMERE, ORBACTIV, BAXDELA, KIMYRSA, and ORBACTIV — effectively CorMedix's closest historical peer.
• Paratek Pharmaceuticals: Commercial-stage anti-infective company (acquired by Novo Holdings in 2023) that developed and commercialized omadacycline and other differentiated hospital antibiotics, directly comparable to CorMedix's Melinta portfolio strategy.

Emerging players

• Theratechnologies: Specialty biopharma commercializing hospital and specialty therapeutics with similar institutional sales channels. Comparable in size and development stage and competes in similar end markets.
• Harrow Health: Specialty pharmaceutical company focused on branded ophthalmic and hospital products, sharing a comparable niche-specialty commercial model and a portfolio-acquisition growth strategy similar to CorMedix's Melinta playbook.
• Nabriva Therapeutics: Specialty biopharma commercializing hospital antibiotics for resistant infections, sharing CorMedix's anti-infective focus and hospital channel orientation at a smaller commercial scale.

Broad incumbents

• Becton, Dickinson and Company (BD): Global medical device incumbent with a leading vascular access and drug delivery portfolio. While BD does not market a competing catheter lock solution, it is the dominant supplier of central venous catheters and infusion sets into which DefenCath is administered, making it a critical channel partner and adjacent incumbent.
• ICU Medical: Medical device company specializing in IV therapy, infusion sets, and catheter-related products. Operates adjacent to CorMedix in the vascular access ecosystem, particularly relevant for DefenCath's deployment in hospital and dialysis settings.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cormedixinc
• Facebookfacebook.com/133854449997528
• LinkedInlinkedin.com/company/cormedix-inc-

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries1 record

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CorMedix